Guardant Health Named to TIME100 Most Influential Companies
31 Maggio 2024 - 2:05PM
Business Wire
Guardant’s Impact, Innovation, Ambition, and
Success Contributed to the Recognition
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology
company, today announced its inclusion in the fourth-annual TIME100
Most Influential Companies list, highlighting companies making an
extraordinary impact around the world.
TIME solicited nominations across sectors, and polled its global
network of contributors and correspondents, as well as outside
experts. TIME editors then evaluated companies on key factors,
including impact, innovation, ambition, and success. The result is
a diverse group of 100 businesses helping chart an essential path
forward. Guardant was included in the Innovators section of the
list, which includes 20 companies across diverse industries.
“We tirelessly pursue our mission to conquer cancer with data
because our progress means giving more people more time free from
cancer,” said Helmy Eltoukhy, chairman, Co-CEO, and Co-Founder of
Guardant Health. “We are grateful for this recognition among other
leading companies as it is a strong reflection of our entire team’s
commitment to transforming patient care through critical insights
into disease drivers, advanced blood and tissue tests, real-world
data, and AI analytics.”
Guardant recently reached several significant milestones,
including announcing that it has achieved 500 peer-reviewed
publications and 500,000 patient tests delivered. Earlier this
month, the company completed the Molecular and Clinical Genetics
Panel of the U.S. Food and Drug Administration (FDA)’s Medical
Devices Advisory Committee, which strongly recommended FDA approval
of the company’s Shield™ blood test for colorectal cancer screening
in adults age 45 and older who are at an average risk for the
disease. This included a panel voting that Shield’s benefits as a
primary non-invasive screening option outweigh any potential risks.
A decision about Shield’s approval is expected by the FDA later
this year.
See the full list here: time.com/100companies.
About Guardant Health
Guardant Health is a leading precision oncology company focused
on guarding wellness and giving every person more time free from
cancer. Founded in 2012, Guardant is transforming patient care by
providing critical insights into what drives disease through its
advanced blood and tissue tests, real-world data and AI analytics.
Guardant tests help improve outcomes across all stages of care,
including screening to find cancer early, monitoring for recurrence
in early-stage cancer, and helping doctors select the best
treatment for patients with advanced cancer. For more information,
visit guardanthealth.com and follow the company on LinkedIn, X
(Twitter) and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240531317151/en/
Investor Contact: Zarak Khurshid
investors@guardanthealth.com
Media Contact: Melissa Marasco press@guardanthealth.com
+1 650-647-3711
Grafico Azioni Guardant Health (NASDAQ:GH)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Guardant Health (NASDAQ:GH)
Storico
Da Set 2023 a Set 2024